bleomycin / Generic mfg. - LARVOL DELTA

S1PR3 Inhibition in alveolar epithelial cells alleviates pulmonary fibrosis by enhancing alveolar barrier function. (PubMed, Respir Res) - "S1PR3 in alveolar epithelial cells plays a critical role in maintaining alveolar-capillary barrier integrity during pulmonary fibrosis. Targeted inhibition of S1PR3 strengthens tight junctions and alleviates inflammation, suggesting that S1PR3 may serve as a promising therapeutic target for PF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CLDN4 • OCLN • TJP1

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience. (ASH 2025) - "ACVD (Adriamycin 25 mg/m², Cyclophosphamide 400 mg/m², Vinblastine 6 mg/m² (max 10 mg) and Dacarbazine 375 mg/m²) is a modified chemotherapy regimen from ABVD given IV on day 1 and day 15 and repeated every 28 days for 6 cycles, replacing bleomycin with low dose cyclophosphamide to further optimize efficacy and reduce pulmonary and gonadal toxicity. Brentuximab vedotin is added to ACVD (ACVD-BV) in those cases of positive PET following 2 cycles of ACVD...Sperm banking was performed for 18/34 (53%) males before starting chemotherapy, and only 3/22 (13.617%) females received leuprorelin (GnRH agonist) during the chemotherapy... This study shows a favorable advantage of ACVD /ACVD-BV chemotherapy in treating advanced-stage HL where majority of cases gained their gonadal functions. However, limitations include retrospective design, missing baseline gonadal function evaluation, particularly semen analyses, and inconsistent hormone level documentation...."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium (ASH 2025) - "Other regimens included BEACOPP (n=39; 5.5%), platinum-based protocols (n=8; 1.1%), and regimens with Brentuximab Vedotin (n=3; 0.4%) or Nivolumab (n=7; 1.0%)...Bleomycin toxicity was reported in 48 (7%) patients and 4 patients succumbed to the same...iPET response was the strongest predictor of event-free survival, outperforming traditional prognostic markers like the IPS score. Combining iPET and IPS can be further used to stratify risk, though this requires validation in prospective cohorts."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Do patients with classic Hodgkin's lymphoma treated with ABVD in low-middle income countries have a higher risk of neutropenia/febrile neutropenia without G-CSF support? a single-center retrospective study (ASH 2025) - "Introduction: Patients with Hodgkin lymphoma (cHL) who receive adriamycin, bleomycin, vinblastine, anddacarbazine (ABVD) chemotherapy commonly experience neutropenia; however, the incidence of febrileneutropenia is rare. The omission of G-CSF support in patients treated with ABVD appears to be both safe andresource-saving in LMIC. Despite the observed higher incidence of stage IV disease and B symptoms—indicative of delays in diagnosis and referral and suggesting a more clinically challenging population—febrile neutropenia was infrequent and did not adversely affect progression-free survival (PFS) or overallsurvival (OS). To our knowledge, this study represents the largest cohort of classic Hodgkin lymphoma(cHL) patients from low- and middle-income countries (LMIC) assessed for neutropenia and febrileneutropenia following ABVD treatment."

Retrospective data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia

Dysregulated lung microbiota impaired hematopoietic stem cell function in mice with pulmonary diseases. (ASH 2025) - "Although the biomass of thelung microbiota is lower than gut microbiota, it also exerts significant influence on the host's immunefunction, susceptibility to diseases, and therapy responses Given that pulmonary microbial dysbiosisemerges as a hallmark of lung diseases and critically modulates systemic immune regulation, wehypothesized that lung microbial communities may also serve as a pivotal communicator bridgingpulmonary pathophysiology and bone marrow HSC homeostasis.In this study, utilizing PM2.5-induced lung injury and bleomycin-induced pulmonary fibrosis models, weidentified pulmonary microbial dysbiosis as a critical pathogenic conduit leading to bone marrow HSCdysfunction...Taxonomicanalysis pinpointed Prevotella melaninogenica as a key microbial contributor for HSC dysfunction.Combined single-cell sequencing and gene editing revealed IL-6 signaling pathway as the principalmechanism underlying hematopoietic impairment.Collectively, our findings delineate a..."

Preclinical • Fibrosis • Hematological Disorders • Immunology • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • IL6

Reduced pulmonary function and posterior cerebral artery perfusion among Hodgkin lymphoma survivors. (ASH 2025) - "Our study demonstrates that a reduced FEV1/FVC was significantly associated with anegative correlation between the anterior and posterior cerebral blood flow in response to exercise in HLsurvivors. These results may provide a physiological explanation for our previous findings showing thatreduced expiratory volume was associated with impaired visuomotor and visual processing speedoutcomes among HL survivors and suggests that interventions that target the posterior circulation insurvivors with reduced FEV1/FVC may improve neurocognitive outcomes."

Alzheimer's Disease • Cognitive Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Fertility outcomes following beacopp and ebeacopp chemotherapy in Hodgkin's lymphoma: A systematic review (ASH 2025) - "It can beeffectively treated with bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride (Adriamycin),cyclophosphamide, vincristine sulfate (Oncovin), procarbazine hydrochloride, and prednisone (BEACOPP)and escalated-BEACOPP chemotherapy. HL treatment can be done with BEACOPP/ eBEACOPP, but it can result in significant gonadotoxicity. Bothmale and female patients showed signs of infertility, with significant hormonal disturbances. PET-adapted regimens reduced POI and improved recovery of gonadal function in both sexes; manysurvivors, especially young patients with fertility preservation, were able to achieve pregnancies andparenthood."

Review • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infertility • Lymphoma • Sexual Disorders • Women's Health

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis (ASH 2025) - "The BV-AVD (brentuximab vedotin-doxorubicin, vinblastine, dacarbazine) regimen for cHL improves overall survival in advanced stagedisease in comparison to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), however, thecomparative incidence of CINV with BV-AVD relative to ABVD is not well described...All patientsreceived anti-emetic prophylaxis of palonosetron and dexamethasone with the first cycle of treatment.The median age of diagnosis for the ABVD group (30 years) and the BV-AVD group (34 years) were similar(p=0.48)... We observed a higher incidence of severe nausea in patients with cHL who were treatedwith BV-AVD as compared to ABVD, when receiving the same standard anti-emetic prophylaxis. Patientstreated with BV-AVD also experienced more hospitalizations for CINV, combined hospitalizations or EDvisits for CINV, and significant weight loss due to CINV. The results of this study suggest that patientsreceiving BV-AVD for cHL may benefit from more intensive..."

Chemotherapy-Induced Nausea and Vomiting • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4 (ASH 2025) - "However, in resource-limited regions, escalating to BEACOPP can be costly, challenging, and may not be readily available.Moreover, procarbazine is not avaliable in different regions in Latin America, including Brazil, andescalation should use Dacarbazine in this context...The primary endpoint was progression freesurvival and secondary endpoint was complete response (CR) rate after initial therapy. Among 218 newly diagnosed patients with cHL, 31 (14%) were identified with a DS of 4 on iPET.The median age was 29 years (range, 20-74), with 58% female and 64.5% having advanced-stage disease.Initial treatment predominantly consisted of ABVD, except for one patient treated with AVD due toconcerns on pulmonary toxicity of bleomycin... This real-world study demonstrates that escalating treatment to BEACOP-DAC for all patientswith cHL and a DS of 4 did not provide significant benefit regarding treatment response, R/R rates or PFS,as compared to continuing with ABVD/AVD. We..."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

MSC regulates the function of neutrophils through mitochondrial transmission to treat early pulmonary fibrosis (ASH 2025) - "It is currently unclear how MSCs regulate the function of neutrophils during pulmonary fibrosis.In this study, we focused on investigating the regulatory effect of MSCs on the function of neutrophils inthe early stage of pulmonary fibrosis and its new molecular mechanism by constructing a bleomycin-induced mouse pulmonary fibrosis model and an MSC-neutrophil co-culture model.The results showed that the number of neutrophils and neutrophil extracellular traps (NETs) significantlyincreased in the early stage of pulmonary fibrosis induction, and NETs could promote the transformationof pulmonary fibroblasts into myofibroblasts...Interestingly, in the co-culture system,the transfer of mitochondria by MSCs is only triggered when neutrophils produce NETs in response tostimulation. This study reveals the role and molecular mechanism of MSCs in regulating the function ofneutrophils in the early stage of pulmonary fibrosis and proposes new strategies for the development ofnovel MSCs."

Immunology • Pulmonary Disease • Respiratory Diseases

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis (ASH 2025) - "Tacrolimus was the mostreported drug trigger (n=6)followed by gemcitabine (n=5), vincristine (n=5), bevacizumab (n=3), carfilzomib (n=3), 6-mercaptopurine(n=2), methotrexate (n=2), and mitomycin (n=2). Aflibercept, bactrim, bleomycin, capecitabine, cisplatin, cyclophosphamide, cytarabine,dasatinib, deferasirox, dinutuximab, estarylla, ketoprofen, L-asparaginase, modakafusp alfa, PEG-asparaginase, sunitinib, syntheticpsychoactive drugs, tamoxifen, and topotecan were reported as potential triggers for aHUS in one patient each...The pooled rate of treatment with eculizumab was 74% (95% CI, 0.629-0.842, p < 0.01, I2 = 72%),and the pooled rate of renal recovery was 65% (95% CI, 0.525-0.761, p < 0.01, I2 = 55%)...AKI and hematological abnormalities in these patients should prompt an emergent work-up and treatment. Current evidenceis primarily derived from case reports, so prospective trials are necessary to establish the incidence, associations, triggers, and outcomes..."

Retrospective data • Review • Acute Kidney Injury • Acute Lymphocytic Leukemia • Anemia • Atypical Hemolytic Uremic Syndrome • B Acute Lymphoblastic Leukemia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Complement-mediated Rare Disorders • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Nephrology • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Thrombocytopenia • Urothelial Cancer

Resveratrol attenuates pulmonary fibrosis by inhibiting alveolar epithelial senescence via targeting SASP-related proteins: an integrated bioinformatics-experimental study. (PubMed, Front Pharmacol) - "The efficacy of RES was evaluated through in vitro experiments using bleomycin (BLM)-induced senescent A549 alveolar epithelial cells and in vivo studies in a BLM-induced PF mouse model (C57BL/6J)...Resveratrol effectively inhibits alveolar epithelial cell senescence and ameliorates pulmonary fibrosis, likely by targeting key senescence-associated pathways (e.g., SERPINE1, MMP2, IL-6). This study provides a promising transdisciplinary strategy for anti-fibrotic drug discovery and highlights RES as a potential therapeutic candidate for PF."

Journal • Immunology • Inflammation • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • IL6 • MMP2 • SERPINE1 • STAT3 • TP53

Mesenchymal stromal cells preserve alveolar macrophages by inducing Sesn2 expression via lactic acid production in a mouse model of bleomycin-induced lung injury. (PubMed, Cell Transplant) - "These findings provide mechanistic insight into how MSCs exert tissue-protective functions via the modulation of tissue-resident macrophages, and identify Sesn2 as a key molecule involved in this process. Our study underscores the immunomodulatory capacity of MSCs and their therapeutic relevance in lung injury."

Journal • Preclinical • Inflammation • Pulmonary Disease • Respiratory Diseases • Transplantation • HIF1A • SESN2

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis. (PubMed, Front Microbiol) - "In this study, we employed a bleomycin induced SSc model to investigate the effects of MSCs on pulmonary fibrosis and gut microbiota in SSc using transcriptomic, microbial metagenomic, and metabolomic analyses...Correlation analysis demonstrated significant associations among transcriptomic, microbiomic, and metabolomic datasets. Collectively, our findings indicate that MSCs may alleviate SSc pulmonary fibrosis by reshaping the gut microbiota, thereby offering novel scientific insights for the investigation of clinical treatment targets for SSc."

Journal • Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Targeting aldose reductase in pulmonary fibrosis: Blocking de novo fatty acid synthesis halts pro-fibrotic M2 polarization. (PubMed, Int J Biol Macromol) - "Here, we observed elevated AR expression and activity in the serum of patients with IPF and in the lungs of mice and rats with bleomycin - induced pulmonary fibrosis. Our findings indicate that AR plays a crucial role in pulmonary fibrosis by activating ERK-MYC signaling, promoting the expression of FASN and ACC1, enhancing fatty acid synthesis, and inducing macrophage M2 polarization. Notably, Epalrestat-an aldose reductase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of diabetic neuropathy-exhibits potent antifibrotic effects in preclinical models, which supports its immediate clinical applicability for the repurposing of IPF treatment."

Journal • Diabetes • Diabetic Neuropathy • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Metabolic Disorders • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • ACACA • AKR1B1 • FAS • FASN • IL4

CILP attenuates pulmonary fibrosis through the TGF-β1/SMAD3 pathway. (PubMed, Eur J Med Res) - "In the bleomycin (BLM)-induced mouse model of pulmonary fibrosis, intravenous administration of CILP (1 μg/g body weight, administered every 2 days for 4 weeks) reduced lung collagen deposition (Masson staining) by 38% (p  0.05), suggesting potential lung tissue-specific action of CILP with minimal systemic off-target risk. In conclusion, CILP inhibited TGF-β1-induced fibrosis via its negative feedback loop, and may act as a promising candidate for the precaution and treatment of IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • COL1A1 • SMAD3 • TGFB1

Pharmacological Profile and Therapeutic Evaluation of ROC-101, a Potent and Selective ROCK Inhibitor, in Arterial Hypertension and Pulmonary Fibrosis. (PubMed, Pharmacol Res) - "Herein, we present a novel selective inhibitor of ROCK1 and ROCK2 (pan-ROCK), ROC-101 (previously known as KD045), and demonstrate its activity as an antifibrotic agent. ROC-101 was efficacious in three different rodent models of pulmonary parenchymal, vascular, and airway diseases: 1) ROC-101 treatment reduced airway hypersensitivity to methacholine in an ovalbumin-induced asthma model and had blood pressure-lowering effects consistent with the role of ROCK in smooth muscle contractility and confirming in vivo target engagement; 2) ROC-101 showed efficacy in attenuating pulmonary arterial hypertension in the semaxanib/hypoxia-induced disease model; and 3) in the bleomycin-induced lung fibrosis model, ROC-101 demonstrated disease-modifying activity in the fibrotic lung, lowering collagen deposition, improving histology, reducing immune cell infiltration, and decreasing ROCK target phosphorylation. These in vivo and functional assessments support the development of..."

Journal • Asthma • Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • CTGF

Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach. (PubMed, Case Rep Oncol Med) - "The first patient with Stage IIIB cHL achieved a complete response (CR) with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) prior to pregnancy but relapsed at 10 weeks of gestation. After delivery, both patients underwent ICE (ifosfamide, carboplatin, and etoposide), followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). These cases highlight the balance needed to maintain control of disease to allow a safe and uneventful pregnancy."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation

Periodic asymmetric field enhances electrofusion of nanoscale lipid systems. (PubMed, Nat Commun) - "These PAF-MED-synthesized cLNPs demonstrate improved fusion efficiency, augmented targeting capability, and superior therapeutic efficacy in bleomycin-induced pulmonary fibrosis murine models. This approach represents a unique advancement in the nanoscale manipulation of drug carriers towards better bio-functionality and reproducibility beyond conventional capability of electrofusion."

Journal • Immunology • Pulmonary Disease • Respiratory Diseases

Adipocyte Mesenchymal Stem Cells Derived Exosomes Improve Bleomycin-Induced Lung Fibrosis in Rat. (PubMed, Artif Organs) - "The results suggest that inhalation delivery of ADMSCs-derived exosomes may provide a more effective and targeted strategy for treating pulmonary fibrosis compared to systemic administration."

Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CRP

Antifibrotic Efficacy of Daclatasvir Against Pulmonary Fibrosis: Insights From Network Pharmacology, Molecular Docking, Dynamics, and Preclinical Evaluations. (PubMed, Chem Biodivers) - "The present study evaluated DAC in a bleomycin (BLM)-induced PF rat model, integrating network pharmacology, molecular docking, and molecular dynamics (MD) simulation to decipher its mechanisms...PCA analyses also confirmed complex stability, comparable to known inhibitors vorinostat and mocetinostat...Interestingly, a higher dose (12.4 mg/kg/day) showed reduced efficacy and increased lung index, indicating dose sensitivity. These findings suggest that DAC possesses dose-dependent antifibrotic activity in PF and warrants further exploration as a repurposable therapeutic candidate."

Journal • Preclinical • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • HDAC2 • HIF1A

Airway Delivery of Encapsulated Cytokine-Secreting Cells for Local Immunomodulation in Inflammatory Lung Diseases. (PubMed, Res Sq) - "In a bleomycin pulmonary fibrosis model, the platform enables durable and sustained delivery of IL-10 to alleviate hypoxemia and rescue lung architecture. Safety and biocompatibility were further confirmed in a large animal model, highlighting the clinical potential of the platform for the treatment of inflammatory lung diseases."

Journal • Acute Respiratory Distress Syndrome • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL10

Synthesis of a hemicyanine-based near-infrared fluorescent probe for the diagnosis of pulmonary fibrosis and acute lung injury. (PubMed, Anal Chim Acta) - "The development of HD-LACTB showcases a conceptual advance in probe design: a mitochondria-targeted, enzyme-responsive NIR fluorophore that bridges a critical gap in lung disease imaging. This strategy illustrates how rationally engineered chemical probes can provide unprecedented molecular specificity in vivo, heralding a new class of materials-based diagnostics for respiratory diseases. By enabling precise, noninvasive visualization of pathological processes at the organelle level, HD-LACTB paves the way for innovative diagnostic approaches in pulmonary medicine."

Journal • Acute Lung Injury • Fibrosis • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • LACTB

Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis. (PubMed, FASEB J) - "In bleomycin-induced mice, valproic acid (VPA) lowered collagen deposition by ~60% and normalized gene expression. MYCT1 and PLEKHA1 act as anti-senescence factors, while PCDH12 and PLXND1 act as pro-fibrotic drivers. The four-gene model shows strong diagnostic potential, and VPA may serve as a therapeutic candidate targeting ECS in IPF."

Journal • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • COL1A1 • MYCT1 • PLEKHA1 • TGFB1